

SANOFI S.A.

ISIN: FR0000120578

WKN: 12057

Asset Class: Stock

Company

2022/01/21 17:39:37



Price

90.94

EUR

Difference

-2.13% (-1.98)

Contact Details

SANOFI

Tel: 33-1-53-77-40-00

--

Fax: 33-1-53-77-44-03

54, rue La Boétie

Web: <http://www.sanofi.com>

75008 Paris

E-mail: investor.relations@sanofi.com

Company Profile

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2020		2019		2018	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	33,703,000,000		28,611,000,000		24,579,000,000	
Common stock capital		2,518,000,000		2,508,000,000		2,495,000,000
Fixed assets	80,826,000,000		84,125,000,000		86,829,000,000	
Equity capital of a company		63,147,000,000		59,108,000,000		59,035,000,000
Cash and cash equivalents	13,915,000,000		9,742,000,000		6,925,000,000	
Accrued liabilities		7,219,000,000		7,353,000,000		6,883,000,000
Other assets	-		-		-	
Current liabilities		19,248,000,000		20,381,000,000		17,376,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		32,134,000,000		33,247,000,000		34,997,000,000
Different income		-		-		-
Other liabilities		2,469,000,000		2,482,000,000		2,693,000,000
Total assets	114,529,000,000	114,529,000,000	112,736,000,000	112,736,000,000	111,408,000,000	111,408,000,000

Balance notes

	2020	2019	2018
Accounting standard	IFRS	IFRS	IFRS
Employees	99,412	100,409	104,226
Equity ratio	55.26%	52.58%	53.13%
Debt-equity ratio	80.95%	90.17%	88.21%

Others

	2020	2019	2018
Tax Expense Rate	13.13%	4.93%	10.92%

Income statement

	2020	2019	2018
Turnover	36,041,000,000	36,126,000,000	34,463,000,000
Net income	12,314,000,000	2,907,000,000	4,319,000,000
EBIT	14,241,000,000	3,289,000,000	4,825,000,000
Operating income before taxes	13,804,000,000	2,822,000,000	4,405,000,000
Cash Flow	7,449,000,000	7,744,000,000	5,547,000,000
Net interest income	-437,000,000	-467,000,000	-420,000,000
Research and development expenses	5,527,000,000	6,015,000,000	5,890,000,000
Income taxes	1,813,000,000	139,000,000	481,000,000
Result from investments in subsidiaries, associates and other	359,000,000	255,000,000	499,000,000
Revenues per employee	362,542	359,788	330,656

Board of Directors

Serge Weinberg	Chairman of Supervisory Board
Bernard Charlès	Member of Supervisory Board
Melanie Lee	Member of Supervisory Board
Thomas Südhof	Member of Supervisory Board
Barbara Lavernos	Member of Supervisory Board
Carole Piwnica	Member of Supervisory Board
Christian Senectaire	Member of Supervisory Board
Christophe Babule	Member of Supervisory Board
Diane Souza	Member of Supervisory Board
Fabienne Lecorvaisier	Member of Supervisory Board
Gilles Schnepf	Member of Supervisory Board
Lise Kingo	Member of Supervisory Board
Marion Palme	Member of Supervisory Board
Patrick Kron	Member of Supervisory Board
Rachel Duan	Member of Supervisory Board

Members of Management Board

Paul Hudson	Chairman of Managing Board
John Reed	Member of Executive Committee
Arnaud Robert	Member of Executive Committee
Bill Sibold	Member of Executive Committee
Brendan O'Scullaghan	Member of Executive Committee
Jean-Baptiste Chasseloup de Chatillon	Member of Executive Committee
Julie Van Ongevalle	Member of Executive Committee
Karen Linehan	Member of Executive Committee
Natalie Bickford	Member of Executive Committee
Olivier Charmeil	Member of Executive Committee
Thomas Triomphe	Member of Executive Committee